

The formal total synthesis of drarmacidin B, *trans*-drarmacidin C, and *cis*- and *trans*-dihydrohamacanthins A

Neil K. Garg and Brian M. Stoltz*


The Arnold and Mabel Beckman Laboratory for Chemical Synthesis, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA

Received 7 February 2005; revised 9 February 2005; accepted 9 February 2005

Abstract—A facile formal total synthesis of drarmacidin B, *trans*-drarmacidin C, and *cis*- and *trans*-dihydrohamacanthins A is presented. Our approach to these bis(indole) alkaloids involves a one-pot, four-step cross-coupling/deprotection sequence where complete halogen selectivity is observed. A related approach to access the dihydrohamacanthins is also described.

© 2005 Elsevier Ltd. All rights reserved.

Over the past several decades, biologically active natural products isolated from marine organisms have served as promising leads in the area of drug discovery.¹ The drarmacidin family of bis(indole) alkaloids represents an emerging class of cytotoxic natural products obtained from deep-water marine sponges.² In 2002, we described the total synthesis of drarmacidin D (**1**, Scheme 1).³ Our route to **1** featured a series of thermally controlled, halogen-selective Suzuki cross-couplings of **2**, **3**, and **4** to construct the bis(indole)pyrazine




Scheme 1.

Keywords: Suzuki; Heterocycles; Bis(indole); Drarmacidin; Palladium.

* Corresponding author. Tel.: +1 626 395 6064; fax: +1 626 564 9297; e-mail: stoltz@caltech.edu

framework of the natural product. Importantly, the 6-bromoindole moiety could be maintained throughout these reactions. Herein, we report an extension of this approach to achieve the formal total synthesis of several related bis(indole) alkaloids.


A retrosynthetic strategy for the preparation of drarmacidin B (**5**) and *trans*-drarmacidin C (**6**) is shown below in Scheme 2. Based on conditions reported by Horne, each of the bis(indole) alkaloids can be accessed from unsaturated derivative **7** in a single step.⁴ Pyrazine **7**,



Scheme 2.

in turn, would be obtained from two halogen-selective Suzuki cross-coupling reactions of boronic acid **8** with a dihalogenated pyrazine (**9**). We anticipated that the boronic acid fragment employed in our synthesis of drarmacidin D (i.e., **4**) could be utilized as a surrogate for **8** in order to achieve our current goals. However, the success of our plan would depend highly on the choice of halogens for pyrazine **9**.

In order to probe the limits of our halogen-selective Suzuki cross-coupling methodology, we chose to use known dibromide **10**⁵ as the critical pyrazine fragment (Scheme 3). In a one-pot, four-step transformation, an excess of 6-bromoindoloboronic acid (**4**) was exposed to dibromopyrazine **10** under our standard




Scheme 3.


cross-coupling conditions. Following quenching with KOH/ethanol, the deprotected pyrazine product (**7**) was obtained in 54% yield.⁶ Notably, although four bromides were introduced in the reaction mixture, only the two pyrazinyl bromides were reactive in the presence of Pd(0) at 50 °C. This rapid synthesis of bis(indole) pyrazine **7** constitutes a formal total synthesis of both drarmacidin B (**5**) and *trans*-drarmacidin C (**6**).^{4,7,8}

These halogen-selective Suzuki couplings also have great potential for assembling a related family of natural products, the dihydrohamacanthins (Scheme 4).⁹ In this scenario, the desired alkaloids (**11** and **12**) would be obtained from their pyrazinone counterparts (**13** and **14**), using the method established by Horne and co-workers.¹⁰ Intermediates **13** and **14**, in turn, would arise via cross-coupling chemistry using indole fragments **15** and **16**, as well as pyrazine fragments **17** and **18**, in a manner similar to that describe above. Halogen-selective cross-couplings will be crucial to prepare all of the halogenation patterns present in this series of natural products (**11a–d**, **12a–d**).

To demonstrate the feasibility of this approach, we prepared one of the dihydrohamacanthin natural products (**11c**, Scheme 5). In the first Suzuki coupling, dihalopyrazine **3** and bromoindole **4** were treated with Pd(0) at 23 °C to afford coupled indolopyrazine **19**.³ Dibromide **19**, in turn, was subjected to boronic ester **20** in the presence of Pd(0) at 50 °C to produce bis(indole)pyrazine **21** in 53% yield. In both cases, complete halogen-selectivity was observed. Subsequent removal of all protecting groups furnished pyrazinone **22**,¹¹ which has previously



Scheme 4.



Scheme 5.

been converted to the natural product (**11c**) in a single step.^{10,12}

In summary, we have completed the formal total synthesis of dragmacidin B and *trans*-dragmacidin C. Our route features a one-pot, four-step halogen-selective cross-coupling/deprotection sequence to construct the bis(indole) scaffold of our targets. In addition, we have applied this methodology to the formal synthesis of a dihydroamcanthins natural product.

Acknowledgements

The authors thank the NIH-NIGMS (R01 GM65961-01), the NDSEG (predoctoral fellowship to N.K.G.), AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Pfizer, Merck, Amgen, Research Corporation, Roche, and GlaxoSmithKline for generous funding.

References and notes

- (a) Aygün, A.; Pindur, U. *Curr. Med. Chem.* **2003**, *10*, 1113–1127; (b) Faulkner, D. *J. Nat. Prod. Rep.* **2002**, *19*, 1–48; (c) Pindur, U.; Lemster, T. *Curr. Med. Chem.* **2001**, *8*, 1681–1698; (d) Yang, C.-G.; Huang, H.; Jiang, B. *Curr. Org. Chem.* **2004**, *8*, 1691–1720.
- For the isolation of the piperazine-containing dragmacidins, see: (a) Kohmoto, S.; Kashman, Y.; McConnell, O. J., Jr.; Rinehart, K. L., Jr.; Wright, A.; Koehn, F. *J. Org. Chem.* **1988**, *53*, 3116–3118; (b) Morris, S. A.; Andersen, R. J. *Tetrahedron* **1990**, *46*, 715–720; (c) Fahy, E.; Potts, B. C. M.; Faulkner, D. J.; Smith, K. *J. Nat. Prod.* **1991**, *54*, 564–569. For the isolation of the pyrazinone-containing dragmacidins, see: (d) Wright, A. E.; Pomponi, S. A.; Cross, S. S.; McCarthy, P. *J. Org. Chem.* **1992**, *57*, 4772–4775; (e) Capon, R. J.; Rooney, F.; Murray, L. M.;

- Collins, E.; Sim, A. T. R.; Rostas, J. A. P.; Butler, M. S.; Carroll, A. R. *J. Nat. Prod.* **1998**, *61*, 660–662; (f) Cutignano, A.; Bifulco, G.; Bruno, I.; Casapullo, A.; Gomez-Paloma, L.; Riccio, R. *Tetrahedron* **2000**, *56*, 3743–3748; (g) Wright, A. E.; Pomponi, S. A.; Jacobs, R. S. PCT Int. Appl. WO 9942092 August 26, 1999.
- Garg, N. K.; Sarpong, R.; Stoltz, B. M. *J. Am. Chem. Soc.* **2002**, *124*, 13179–13184.
 - Miyake, F. Y.; Yakushijin, K.; Horne, D. A. *Org. Lett.* **2000**, *2*, 3185–3187.
 - Ellingson, H. *J. Am. Chem. Soc.* **1949**, *71*, 2798–2800.
 - A vial charged with dibromopyrazine **10** (15.1 mg, 0.0635 mmol), boronic acid **4** (75 mg, 0.190 mmol), and tetrakis(triphenylphosphine)palladium(0) (11 mg, 0.0095 mmol), was evacuated and purged with N₂. Deoxygenated benzene (1.2 mL), deoxygenated methanol (250 μL), and deoxygenated 2 M aq Na₂CO₃ (105 μL) were then added. The reaction mixture was sparged with argon for 3 min. The vial was then sealed, heated to 50 °C for 84 h, and cooled to 23 °C. EtOH (7 mL) and KOH (500 mg) were added. The reaction mixture was heated to 50 °C for 20 h, cooled to 23 °C, then quenched by pouring into 10% (w/v) aq citric acid (20 mL). EtOAc (30 mL) was added, and the layers were partitioned. The aqueous phase was further extracted with EtOAc (2 × 30 mL). The combined organic layers were washed with brine (15 mL), dried over MgSO₄, and evaporated under reduced pressure. The crude product was purified by flash chromatography (10:1 CH₂Cl₂/MeOH eluent), then further purified by preparative thin layer chromatography (2:1 EtOAc/hexanes eluent) to afford known bis(indole) **7**⁴ (16 mg, 54% yield) as a yellow powder.
 - Treatment of **7** with NaBH₃CN in formic acid leads to the formation of dragmacidin B (**5**), while the analogous reaction conducted in acetic acid results in production of *trans*-dragmacidin C (**6**)⁴.
 - Kawasaki, T.; Ohno, K.; Enoki, H.; Umamoto, Y.; Sakamoto, M. *Tetrahedron Lett.* **2002**, *43*, 4245–4248.
 - Casapullo, A.; Bifulco, G.; Bruno, I.; Riccio, R. *J. Nat. Prod.* **2000**, *63*, 447–451.
 - Miyake, F. Y.; Yakushijin, K.; Horne, D. A. *Org. Lett.* **2002**, *4*, 941–943.
 - A reaction tube charged with indolopyrazine **19** (125 mg, 0.335 mmol), boronic ester **20** (90 mg, 0.168 mmol), and tetrakis(triphenylphosphine)palladium(0) (35 mg, 0.030 mmol), was evacuated and purged with N₂. Deoxygenated benzene (3.5 mL), deoxygenated methanol (690 μL), and deoxygenated 2 M aq Na₂CO₃ (180 μL) were then added. The reaction mixture was sparged with argon for 2 min. The tube was then sealed, heated to 50 °C for 48 h, cooled to 23 °C, and quenched by the addition of Na₂SO₄ (200 mg). The reaction mixture was filtered over a plug of SiO₂ (CH₂Cl₂ eluent) and the solvents were evaporated under reduced pressure. The crude product was purified by flash chromatography (2:1 CH₂Cl₂/hexanes eluent), to afford bis(indole) **21** (62 mg, 53% yield), which was used immediately in the subsequent reaction. Bis(indole) **21** (30 mg, 0.043 mmol) was dissolved in 1.0 M TBAF in THF (1 mL, 1 mmol) and heated to 65 °C for 16 h. After cooling to 23 °C, the solvent was removed under reduced pressure and CH₂Cl₂ (5 mL) was added. The organic layer was washed with H₂O (2 × 1 mL) and brine (1 mL), concentrated to dryness, then purified by flash chromatography (CH₂Cl₂ eluent) to give the intermediate bis-*N*-deprotected product (16 mg, 89% yield). A mixture of this intermediate (1.5 mg, 0.0034 mmol), LiI (100 mg, 0.75 mmol), and collidine (1 mL) was heated to

130 °C for 4 days. After cooling to 23 °C, the reaction mixture was diluted with EtOAc (5 mL), washed with H₂O (3 × 5 mL), and brine (2 mL), then dried by passage over a plug of SiO₂ (EtOAc eluent). The solvent was removed

under reduced pressure to afford known pyrazone **22**¹⁰ (1.0 mg, 69% yield).

12. Reduction of **22** with NaBH₃CN leads to the production of a **11c**.